Humasis Co

Humasis Co Revenue per Employee

The Revenue per Employee of Humasis Co (205470.KQ) as of Nov 10, 2026 is 124.95 M KRW. In the previous year, Revenue per Employee was 105.45 M KRW — a change of 18.49% (higher).

Revenue per Employee

124.95 MKRW

YoY

18.49%

Last updated:

Revenue per Employee of Humasis Co is 2025 124.95 M KRW. Revenue per Employee of Humasis Co was 2024 105.45 M KRW. It decreases by 18.49% higher compared to the previous year.

The Humasis Co Revenue per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Employee
Date
Revenue per Employee
Jan 1, 2018
40.07 M KRW
Jan 1, 2019
37.97 M KRW
Jan 1, 2020
189.70 M KRW
Jan 1, 2021
1.34 B KRW
Jan 1, 2022
1.96 B KRW
Jan 1, 2023
57.37 M KRW
Jan 1, 2024
105.45 M KRW
Jan 1, 2025
124.95 M KRW
The Humasis Co Revenue per Employee history
YEARRevenue per EmployeeYoY
124.95 MKRW+18.49%
105.45 MKRW+83.79%
57.37 MKRW-97.07%
1.96 BKRW+46.44%
1.34 BKRW+603.96%
189.70 MKRW+399.61%
37.97 MKRW-5.25%
40.07 MKRW+13.51%
35.30 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Revenue per Employee of Humasis Co is 124.95 M KRW in 2025.

Revenue per Employee of Humasis Co changed from 105.45 M KRW to 124.95 M KRW, representing a 18.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Employee Humasis Co since 2006 – with annual values, charts, and detailed analysis.

Revenue per employee measures workforce productivity by dividing total revenue by the number of employees. Higher values indicate more efficient operations.

Revenue per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Revenue per Employee's Humasis Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Humasis Co

All Key Metrics — Humasis Co